নিউ জিলণ্ড - ইংরেজি - Medsafe (Medicines Safety Authority)

baxter healthcare ltd - bupivacaine hydrochloride monohydrate 0.5% - solution for injection - 0.5 % - active: bupivacaine hydrochloride monohydrate 0.5%

নিউ জিলণ্ড - ইংরেজি - Medsafe (Medicines Safety Authority)

novartis new zealand ltd - clomifene citrate 50mg - tablet - 50 mg - active: clomifene citrate 50mg excipient: colloidal silicon dioxide lactose monohydrate magnesium stearate maize starch povidone powdered cellulose

নিউ জিলণ্ড - ইংরেজি - Medsafe (Medicines Safety Authority)

pfizer new zealand limited - deferoxamine mesilate 2 g - powder for injection - 2 g - active: deferoxamine mesilate 2 g - monotherapy iron chelation treatment for chronic iron overload, e.g. · transfusional haemosiderosis, as seen in thalassaemia major, sideroblastic anaemia, auto-mmune haemolytic anaemia, and other chronic anaemias. · idiopathic (primary) haemochromatosis in patients in whom concomitant disorders (e.g. severe anaemia, cardiac disease, hypoproteinaemia) preclude phlebotomy · iron overload associated with porphyria cutanea tarda in patients unable to tolerate phlebotomy. · treatment for acute iron poisoning.

নিউ জিলণ্ড - ইংরেজি - Medsafe (Medicines Safety Authority)

pfizer new zealand limited - deferoxamine mesilate 500mg - powder for injection - 500 mg - active: deferoxamine mesilate 500mg - monotherapy iron chelation treatment for chronic iron overload, e.g. · transfusional haemosiderosis, as seen in thalassaemia major, sideroblastic anaemia, auto-mmune haemolytic anaemia, and other chronic anaemias. · idiopathic (primary) haemochromatosis in patients in whom concomitant disorders (e.g. severe anaemia, cardiac disease, hypoproteinaemia) preclude phlebotomy · iron overload associated with porphyria cutanea tarda in patients unable to tolerate phlebotomy. · treatment for acute iron poisoning.

নিউ জিলণ্ড - ইংরেজি - Medsafe (Medicines Safety Authority)

multichem nz limited - doxazosin mesilate 1.213mg equivalent to doxazosin 1 mg - tablet - 1 mg - active: doxazosin mesilate 1.213mg equivalent to doxazosin 1 mg excipient: colloidal silicon dioxide lactose monohydrate magnesium stearate microcrystalline cellulose sodium laurilsulfate sodium starch glycolate

নিউ জিলণ্ড - ইংরেজি - Medsafe (Medicines Safety Authority)

multichem nz limited - doxazosin mesilate 2.426mg equivalent to doxazosin 2 mg - tablet - 2 mg - active: doxazosin mesilate 2.426mg equivalent to doxazosin 2 mg excipient: colloidal silicon dioxide lactose monohydrate magnesium stearate microcrystalline cellulose sodium laurilsulfate sodium starch glycolate

নিউ জিলণ্ড - ইংরেজি - Medsafe (Medicines Safety Authority)

multichem nz limited - doxazosin mesilate 4.852mg equivalent to doxazosin 4 mg - tablet - 4 mg - active: doxazosin mesilate 4.852mg equivalent to doxazosin 4 mg excipient: colloidal silicon dioxide lactose monohydrate magnesium stearate microcrystalline cellulose sodium laurilsulfate sodium starch glycolate

নিউ জিলণ্ড - ইংরেজি - Medsafe (Medicines Safety Authority)

pfizer new zealand limited - methotrexate 10mg (11.11 mg with 10% manufacturing overage);  ; methotrexate 10mg (11.11 mg with 10% manufacturing overage) - tablet - 10 mg - active: methotrexate 10mg (11.11 mg with 10% manufacturing overage)   excipient: lactose monohydrate magnesium stearate maize starch microcrystalline cellulose polysorbate 80 starch active: methotrexate 10mg (11.11 mg with 10% manufacturing overage) excipient: lactose monohydrate magnesium stearate maize starch microcrystalline cellulose polysorbate 80 starch - treatment of breast cancer, gestational choriocarcinoma, and in patients with chorioadenoma destruens and hydatidiform mole. palliation of acute and subacute lymphocytic leukaemia. greatest effect has been observed in palliation of acute lymphoblastic (stem cell) leukaemias. in combination with corticosteroids, methoblastin may be used for induction of remission. the drug is now most commonly used for the maintenance of induced remissions. methoblastin is also effective in the treatment of the advanced states (iii and iv, peters staging system) of lymphosarcoma, particularly in children and in advanced cases of mycosis fungoides.

নিউ জিলণ্ড - ইংরেজি - Medsafe (Medicines Safety Authority)

pfizer new zealand limited - methotrexate 2.5mg (2.78 mg with 10% manufacturing overage);   - tablet - 2.5 mg - active: methotrexate 2.5mg (2.78 mg with 10% manufacturing overage)   excipient: lactose monohydrate magnesium stearate maize starch microcrystalline cellulose polysorbate 80 starch - treatment of breast cancer, gestational choriocarcinoma, and in patients with chorioadenoma destruens and hydatidiform mole. palliation of acute and subacute lymphocytic leukaemia. greatest effect has been observed in palliation of acute lymphoblastic (stem cell) leukaemias. in combination with corticosteroids, methoblastin may be used for induction of remission. the drug is now most commonly used for the maintenance of induced remissions. methoblastin is also effective in the treatment of the advanced states (iii and iv, peters staging system) of lymphosarcoma, particularly in children and in advanced cases of mycosis fungoides.

নিউ জিলণ্ড - ইংরেজি - Medsafe (Medicines Safety Authority)

novartis new zealand ltd - timolol maleate 1.37 mg/g - ophthalmic gel - 1 mg/g - active: timolol maleate 1.37 mg/g excipient: benzalkonium chloride carbomer lysine polyvinyl alcohol sodium acetate trihydrate sorbitol water for injection